Pre-made Catumaxomab benchmark antibody (Bispecific, anti-CD3E;EPCAM therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon;Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Catumaxomab benchmark antibody (Bispecific, anti-CD3E;EPCAM therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon;Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Catumaxomab[1] (trade name Removab) is a rat-mouse hybrid monoclonal antibody which is used to treat malignant ascites, a condition occurring in people with metastasizing cancer. It binds to antigens CD3 and EpCAM. It was developed by Fresenius Biotech and Trion Pharma (Germany).
| Products Name (INN Index) | Pre-Made Catumaxomab Biosimilar, Bispecific, Anti-Cd3E; Epcam Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP |
|---|---|
| INN Name | catumaxomab |
| Target | CD3E |
| Format | Bispecific |
| Derivation | NA |
| Species Reactivity | NA |
| CH1 Isotype | NA |
| VD LC | NA |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | NA |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | Triomab? (Trifunctional?Ab) |
| Previous Name | NA |
| Gm Offical Target Name | CD3E,EPCAM |
| Package |
